investorscraft@gmail.com

Intrinsic Value of Biodesix, Inc. (BDSX)

Previous Close$0.27
Intrinsic Value
Upside potential
Previous Close
$0.27

VALUATION INPUT DATA

This valuation is based on fiscal year data as of 2024 and quarterly data as of .

Data is not available at this time.

Stock Valuation Context

Business Model And Market Position

Biodesix, Inc. operates in the diagnostics and data-driven solutions sector, specializing in advanced blood-based testing for lung diseases, including lung cancer and COVID-19. The company leverages proprietary artificial intelligence and machine learning to deliver actionable insights, supporting personalized treatment decisions for clinicians. Its revenue model is primarily driven by diagnostic test sales, biopharmaceutical partnerships, and data services, positioning it as a niche player in precision medicine. Biodesix competes in a rapidly evolving market, where demand for non-invasive diagnostic tools is growing, particularly in oncology and infectious disease management. The company’s focus on innovative, clinically validated tests differentiates it from traditional lab service providers, though it faces competition from larger diagnostic firms and emerging biotech entrants. Its market position is bolstered by strategic collaborations with healthcare providers and biopharma companies, enhancing its commercial reach and technological credibility.

Revenue Profitability And Efficiency

Biodesix reported revenue of $71.3 million for the fiscal year ending December 31, 2024, reflecting its diagnostic test sales and partnership-driven income streams. However, the company posted a net loss of $42.9 million, with diluted EPS of -$0.33, indicating ongoing challenges in achieving profitability. Operating cash flow was negative at $48.6 million, while capital expenditures totaled $3.2 million, underscoring significant cash burn as it invests in growth and R&D.

Earnings Power And Capital Efficiency

The company’s negative earnings and cash flow highlight its current reliance on external funding to sustain operations. With a capital-intensive business model focused on diagnostic innovation, Biodesix’s capital efficiency remains under pressure. Its ability to scale test volumes and secure recurring revenue from biopharma collaborations will be critical to improving earnings power over time.

Balance Sheet And Financial Health

Biodesix’s balance sheet shows $26.2 million in cash and equivalents against $62.0 million in total debt, raising liquidity concerns given its negative cash flow. The high debt burden relative to cash reserves suggests potential refinancing risks, though the company may rely on equity raises or strategic partnerships to bridge funding gaps. Financial health remains fragile, requiring careful capital management.

Growth Trends And Dividend Policy

Revenue growth is driven by expanding test adoption and biopharma contracts, but profitability remains elusive. The company does not pay dividends, reinvesting all cash flows into growth initiatives. Future trends hinge on commercial execution, regulatory approvals for new tests, and scalability of its AI-driven platform in competitive diagnostic markets.

Valuation And Market Expectations

Market expectations for Biodesix are tempered by its unprofitability and cash burn, though its niche in precision diagnostics offers long-term potential. Valuation likely reflects speculative growth prospects rather than near-term earnings, with investors betting on its ability to capture market share in liquid biopsy and data-driven healthcare solutions.

Strategic Advantages And Outlook

Biodesix’s proprietary technology and focus on lung disease diagnostics provide a differentiated edge, but execution risks persist. The outlook depends on achieving scale, securing additional partnerships, and navigating a capital-intensive growth phase. Success in these areas could position the company as a leader in AI-enhanced diagnostics, though near-term challenges remain significant.

Sources

Company filings, CIK 0001439725

show cash flow forecast

FINANCIAL STATEMENTS FORECAST and PRESENT VALUE CALCULATION

Fiscal year2025202620272028202920302031203220332034203520362037203820392040204120422043204420452046204720482049

INCOME STATEMENT

Revenue growth rate, %NaN
Revenue, $NaN
Variable operating expenses, $mNaN
Fixed operating expenses, $mNaN
Total operating expenses, $mNaN
Operating income, $mNaN
EBITDA, $mNaN
Interest expense (income), $mNaN
Earnings before tax, $mNaN
Tax expense, $mNaN
Net income, $mNaN

BALANCE SHEET

Cash and short-term investments, $mNaN
Total assets, $mNaN
Adjusted assets (=assets-cash), $mNaN
Average production assets, $mNaN
Working capital, $mNaN
Total debt, $mNaN
Total liabilities, $mNaN
Total equity, $mNaN
Debt-to-equity ratioNaN
Adjusted equity ratioNaN

CASH FLOW

Net income, $mNaN
Depreciation, amort., depletion, $mNaN
Funds from operations, $mNaN
Change in working capital, $mNaN
Cash from operations, $mNaN
Maintenance CAPEX, $mNaN
New CAPEX, $mNaN
Total CAPEX, $mNaN
Free cash flow, $mNaN
Issuance/(repurchase) of shares, $mNaN
Retained Cash Flow, $mNaN
Pot'l extraordinary dividend, $mNaN
Cash available for distribution, $mNaN
Discount rate, %NaN
PV of cash for distribution, $mNaN
Current shareholders' claim on cash, %NaN
HomeMenuAccount